Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.18
(-10.0%)
CAD 0.18
(-10.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.45 Million CAD | 52.29% |
| 2022 | 1.61 Million CAD | 37.29% |
| 2021 | 1.17 Million CAD | -43.01% |
| 2020 | 2.05 Million CAD | 68.38% |
| 2019 | 1.22 Million CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | -100.0% |
| 2015 | 2242.00 CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.6 Million CAD | 1.36% |
| 2024 Q1 | 2.57 Million CAD | 4.84% |
| 2023 Q4 | 2.45 Million CAD | -18.38% |
| 2023 Q3 | 3 Million CAD | 17.25% |
| 2023 Q2 | 2.56 Million CAD | 45.45% |
| 2023 Q1 | 1.76 Million CAD | 9.41% |
| 2023 FY | 2.45 Million CAD | 52.29% |
| 2022 Q3 | 1.59 Million CAD | 8.76% |
| 2022 Q4 | 1.61 Million CAD | 0.86% |
| 2022 FY | 1.61 Million CAD | 37.29% |
| 2022 Q1 | 1.09 Million CAD | -6.39% |
| 2022 Q2 | 1.46 Million CAD | 33.7% |
| 2021 Q1 | 1.38 Million CAD | -32.5% |
| 2021 Q2 | 1.31 Million CAD | -5.09% |
| 2021 Q3 | 1.24 Million CAD | -5.47% |
| 2021 Q4 | 1.17 Million CAD | -5.9% |
| 2021 FY | 1.17 Million CAD | -43.01% |
| 2020 Q2 | 1.59 Million CAD | 37.51% |
| 2020 Q3 | 1.72 Million CAD | 8.37% |
| 2020 Q4 | 2.05 Million CAD | 19.23% |
| 2020 FY | 2.05 Million CAD | 68.38% |
| 2020 Q1 | 1.15 Million CAD | -5.23% |
| 2019 Q4 | 1.22 Million CAD | -4.88% |
| 2019 FY | 1.22 Million CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 Q3 | 1.28 Million CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2016 Q2 | - CAD | -100.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q1 | 3479.00 CAD | 21.39% |
| 2016 FY | - CAD | -100.0% |
| 2015 Q2 | 2242.00 CAD | 0.0% |
| 2015 FY | 2242.00 CAD | 0.0% |
| 2015 Q3 | - CAD | -100.0% |
| 2015 Q4 | 2866.00 CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | - CAD | -Infinity% |
| Asep Medical Holdings Inc | 20 Thousand CAD | -12168.36% |
| BetterLife Pharma Inc. | 245.23 Thousand CAD | -900.543% |
| BioVaxys Technology Corp. | - CAD | -Infinity% |
| ChitogenX Inc. | 3.87 Million CAD | 36.679% |
| Defence Therapeutics Inc. | 1.74 Million CAD | -40.495% |
| Entheon Biomedical Corp. | - CAD | -Infinity% |
| Gemina Laboratories Ltd. | 285.32 Thousand CAD | -759.954% |
| Glow Lifetech Corp. | 116.18 Thousand CAD | -2011.885% |
| Lexston Life Sciences Corp. | - CAD | -Infinity% |
| Pharmala Biotech Holdings Inc. | 253.53 Thousand CAD | -867.777% |
| Doseology Sciences Inc. | - CAD | -Infinity% |
| MYND Life Sciences Inc. | 3 Million CAD | 18.211% |
| Nova Mentis Life Science Corp. | - CAD | -Infinity% |
| PharmaTher Holdings Ltd. | - CAD | -Infinity% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 36.005% |
| Telescope Innovations Corp. | - CAD | -Infinity% |